Adverse-Event Free Survival, Hospitalizations, and Mortality in Left Ventricular Assist Device Recipients: A Rural-Urban Cohort Comparison.


Journal

The Journal of cardiovascular nursing
ISSN: 1550-5049
Titre abrégé: J Cardiovasc Nurs
Pays: United States
ID NLM: 8703516

Informations de publication

Date de publication:
Historique:
pubmed: 1 8 2019
medline: 25 9 2020
entrez: 1 8 2019
Statut: ppublish

Résumé

The number of individuals with advanced heart failure (HF) receiving left ventricular assist devices (LVADs) is growing. Postimplantation LVAD recipients return home to both rural and urban locations. The impact of rural or urban living on postimplantation outcomes has not been adequately explored. This cohort study examined adverse event-free survival, hospitalization-free survival, and all-cause mortality between rural and urban LVAD recipients in the first 2 years after implantation. Data from LVAD recipients (N = 141) implanted at a single center in the northeastern United States were analyzed. Recipients of LVAD were designated as rural or urban by county of residence. Adverse events, hospitalizations, and survival time were examined using multivariate Cox proportional hazards models. Thirty-seven percent of LVAD recipients in the cohort were rural. Two-thirds of all LVAD recipients experienced at least 1 adverse event (96/141, 68.1%). Although more urban recipients experienced adverse events, including death, rural versus urban models of both adverse events and survival were nonsignificant (adverse events: log-rank = 1.18, P = .28; hazard ratio [HR], 0.96; 95% confidence interval [CI], 0.57-1.63; P = .89; survival: log-rank =2.81, P = .09; HR, 0.45; 95% CI, 0.17-1.23; P = .12). Rural LVAD recipients experienced significantly more hospitalizations and shorter hospitalization-free survival (log-rank = 6.67, P = .009). However, the HR for survival was nonsignificant (HR, 1.5; 95% CI, 0.94-2.39; P = .08). Frequent adverse events and hospitalizations are of ongoing concern for LVAD recipients. More data are necessary to understand why urban LVAD recipients may experience shorter survival time compared with rural counterparts. Hospitalization may serve as a protective factor for rural LVAD recipients.

Sections du résumé

BACKGROUND
The number of individuals with advanced heart failure (HF) receiving left ventricular assist devices (LVADs) is growing. Postimplantation LVAD recipients return home to both rural and urban locations. The impact of rural or urban living on postimplantation outcomes has not been adequately explored.
OBJECTIVE
This cohort study examined adverse event-free survival, hospitalization-free survival, and all-cause mortality between rural and urban LVAD recipients in the first 2 years after implantation.
METHODS
Data from LVAD recipients (N = 141) implanted at a single center in the northeastern United States were analyzed. Recipients of LVAD were designated as rural or urban by county of residence. Adverse events, hospitalizations, and survival time were examined using multivariate Cox proportional hazards models.
RESULTS
Thirty-seven percent of LVAD recipients in the cohort were rural. Two-thirds of all LVAD recipients experienced at least 1 adverse event (96/141, 68.1%). Although more urban recipients experienced adverse events, including death, rural versus urban models of both adverse events and survival were nonsignificant (adverse events: log-rank = 1.18, P = .28; hazard ratio [HR], 0.96; 95% confidence interval [CI], 0.57-1.63; P = .89; survival: log-rank =2.81, P = .09; HR, 0.45; 95% CI, 0.17-1.23; P = .12). Rural LVAD recipients experienced significantly more hospitalizations and shorter hospitalization-free survival (log-rank = 6.67, P = .009). However, the HR for survival was nonsignificant (HR, 1.5; 95% CI, 0.94-2.39; P = .08).
CONCLUSIONS
Frequent adverse events and hospitalizations are of ongoing concern for LVAD recipients. More data are necessary to understand why urban LVAD recipients may experience shorter survival time compared with rural counterparts. Hospitalization may serve as a protective factor for rural LVAD recipients.

Identifiants

pubmed: 31365445
doi: 10.1097/JCN.0000000000000597
pmc: PMC8381739
mid: NIHMS1733982
doi:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

454-464

Subventions

Organisme : NINR NIH HHS
ID : F31 NR016895
Pays : United States

Références

Heart Fail Clin. 2016 Jul;12(3):323-33
pubmed: 27371510
Card Fail Rev. 2017 Apr;3(1):7-11
pubmed: 28785469
Circ Heart Fail. 2014 Nov;7(6):1003-13
pubmed: 25294625
J Fam Med Dis Prev. 2016;2(2):
pubmed: 28736765
World J Cardiol. 2017 May 26;9(5):407-415
pubmed: 28603587
Circ Heart Fail. 2016 Apr;9(4):e002679
pubmed: 27072859
Heart Lung. 2010 Nov-Dec;39(6):512-20
pubmed: 20561853
Source Code Biol Med. 2008 Dec 16;3:17
pubmed: 19087314
J Health Soc Behav. 2010;51 Suppl:S28-40
pubmed: 20943581
Can J Rural Med. 2005 Summer;10(3):155-61
pubmed: 16079031
J Heart Lung Transplant. 2015 May;34(5):701-9
pubmed: 25582036
J Am Coll Cardiol. 2017 Apr 4;69(13):1715-1717
pubmed: 28359518
Intern Emerg Med. 2018 Sep;13(6):907-913
pubmed: 29273909
Methodist Debakey Cardiovasc J. 2015 Jan-Mar;11(1):33-44
pubmed: 25793028
Support Care Cancer. 2017 Nov;25(11):3561-3568
pubmed: 28639096
J Health Soc Behav. 1995 Mar;36(1):1-10
pubmed: 7738325
BMC Health Serv Res. 2018 Apr 10;18(1):271
pubmed: 29636040
Milbank Mem Fund Q Health Soc. 1973 Winter;51(1):95-124
pubmed: 4198894
Curr Heart Fail Rep. 2013 Sep;10(3):212-8
pubmed: 23797344
J Cardiovasc Nurs. 2014 Sep-Oct;29(5):429-38
pubmed: 24088620
J Health Soc Behav. 1995;Spec No:80-94
pubmed: 7560851
J Heart Lung Transplant. 2015 Dec;34(12):1495-504
pubmed: 26520247
Prehosp Emerg Care. 2019 Jul-Aug;23(4):560-565
pubmed: 30285520
J Heart Lung Transplant. 2014 Jan;33(1):12-22
pubmed: 24418730
J Heart Lung Transplant. 2015 Dec;34(12):1515-26
pubmed: 26681121
J Heart Lung Transplant. 2008 Oct;27(10):1065-72
pubmed: 18926395
J Thorac Dis. 2015 Mar;7(3):527-31
pubmed: 25922735
J Heart Lung Transplant. 2015 Oct;34(10):1292-304
pubmed: 26111595

Auteurs

Windy Alonso (W)

Windy Alonso, PhD, RN Doctoral Student, The Pennsylvania State University, College of Nursing, Hershey. Judith E. Hupcey, EdD, CRNP, FAAN Associate Dean for Research and Professor, Nursing and Medicine, The Pennsylvania State University, College of Nursing, Hershey. Lisa Kitko, PhD, RN, FAHA, FAAN Associate Professor, The Pennsylvania State University, College of Nursing, University Park. Bunny Pozehl, PhD, APRN-NP, FHFSA, FAHA, FAAN Professor and Dorothy Hodges Olson Endowed Chair, University of Nebraska Medical Center, College of Nursing, Omaha. Kevin Kupzyk, PhD Assistant Professor, University of Nebraska Medical Center, College of Nursing, Omaha.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH